|
|
 |
|
Viewing report
|
|
|
|
FDA Office of Orphan Products Development - Developmental Therapeutics Review - Q1 2011
Global Markets Direct, March 2011, Pages: 55
FDA Office of Orphan Products Development – Developmental Therapeutics Review – Q1 2011
Summary
Global Market Direct’s pharmaceuticals report, “FDA Office of Orphan Products Development – Developmental Therapeutics Review – Q1 2011” provides data on the institute’s research and development focus. The report includes information on therapeutics under development, complete with latest updates, and features on discontinued projects (if applicable).
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, institute’s website, and featured press releases, both from institute and industry-specific third party sources, put together by Global Markets Direct’s team of industry experts.
Scope
- Review of therapeutics under development by FDA Office of Orphan Products Development.
- Overview of products under development across various therapy areas.
- Coverage of therapeutic molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of FDA Office of Orphan Products Development with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of FDA Office of Orphan Products Development’s therapeutic products in the last quarter.
- Latest news and deals relating to the products.
Reasons to buy
- Identify new drug targets and therapeutic classes in FDA Office of Orphan Products Development’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying opportunities to fill portfolio gaps.
- Evaluate FDA Office of Orphan Products Development’s position with total access to a detailed information on its therapeutic products development.
- Assess the growth potential of FDA Office of Orphan Products Development in its therapy areas of focus.
- Exploit collaboration and partnership opportunities with FDA Office of Orphan Products Development.
- Avoid Intellectual Property Rights related issues.
|
|
|
|
